Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United Statesadmin2020-05-19T16:22:45+00:00May 19th, 2020|Categories: Press Releases|Tags: 3500xL Dx Genetic Analyzer, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, AML, Analysis Software, Commercial Companion Diagnostics, Companion Diagnostics, D835, FDA Approval, FLT3 mut + AML Patients, FLT3 Mutation Test, Gilteritinib Fumarate, I836, In vitro Diagnostic Test, Internal Tandem Duplication, Invivoscribe, ITD, IVD Kit, LabPMM, LeukoStrat® CDx FLT3 Mutation Assay, Midostaurin, PCR-Based, Precision Diagnostics, Quizartinib, Quizartinib Hydrochloride, Relapsed/Refractory, Rydapt®, TKD, Tyrosine Kinase Domain, United States, US, Xospata®| ⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...] Read More
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.admin2020-05-12T17:03:17+00:00May 12th, 2020|Categories: Press Releases|Tags: ADMIRAL, AML, Astellas, Australia, CE-Marked, China, Clinical Trials, Companion Diagnostics, Europe, FLT3 biomarker, Germany, gilteritinib, Invivoscribe, Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd., ITD, Japan, LabPMM, LeukoStrat® CDx FLT3 Mutation Assay, NMPA, QuANTUM-R, RATIFY, refractory FLT3-mutated AML, relapsed FLT3-mutated AML., Rydapt®, Shanghai, Switzerland, TKD, United States, VANFLYTA®, Xospata®| ⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...] Read More
